2024
Why Do Optimal Targets for Itch and Skin Clearance Matter in Atopic Dermatitis Treatment? Insights from TARGET-DERM AD Registry
Silverberg J, Bunick C, Calimlim B, Grada A, Knapp K, Munoz B, Crawford J, Obi C, Paller A. Why Do Optimal Targets for Itch and Skin Clearance Matter in Atopic Dermatitis Treatment? Insights from TARGET-DERM AD Registry. SKIN The Journal Of Cutaneous Medicine 2024, 8: s461. DOI: 10.25251/skin.8.supp.461.Peer-Reviewed Original ResearchPatient-reported outcomesTreat-to-target recommendationsSkin clearanceAtopic dermatitisOptimal treatmentSkin severityNRS-sleepSkin lesionsNRS painOptimal patient outcomesPartial improvementPatient outcomesNear-complete resolutionAtopic dermatitis treatmentReal-world studyMinimal itchingVIGA-ADOptimal treatment targetsEczema/atopic dermatitisDLQI 0/1Logistic regression modelsCross-sectional analysisItch severityOdds ratioDermatitis treatment
2021
Antibacterial Mechanisms and Efficacy of Sarecycline in Animal Models of Infection and Inflammation
Bunick CG, Keri J, Tanaka SK, Furey N, Damiani G, Johnson JL, Grada A. Antibacterial Mechanisms and Efficacy of Sarecycline in Animal Models of Infection and Inflammation. Antibiotics 2021, 10: 439. PMID: 33920812, PMCID: PMC8071131, DOI: 10.3390/antibiotics10040439.Peer-Reviewed Original ResearchTetracycline-class antibioticsBroad-spectrum antibiotic useRat paw edema modelPaw edema modelAnti-inflammatory activityWound infection modelSevere acneEdema modelPatient outcomesAntibiotic useMurine modelAnimal modelsDrug AdministrationGut microfloraInfection modelSarecyclineVivo studiesRelevant Gram-positive bacteriaReduced efficacyInfectionAntimicrobial resistanceVivo activityAntibiotic resistanceInflammationReduced activity